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Abstract
Background: Cell–based therapy holds great promises for demyelinating diseases. Human-derived fetal and adult
oligodendrocyte progenitors (OPC) gave encouraging results in experimental models of dysmyelination but their limited
proliferation in vitro and their potential immunogenicity might restrict their use in clinical applications. Virtually unlimited
numbers of oligodendroglial cells could be generated from long-term self-renewing human (h)-derived neural stem cells
(hNSC). However, robust oligodendrocyte production from hNSC has not been reported so far, indicating the need for
improved understanding of the molecular and environmental signals controlling hNSC progression through the
oligodendroglial lineage. The aim of this work was to obtain enriched and renewable cultures of hNSC-derived
oligodendroglial cells by means of epigenetic manipulation.
Methodology/Principal Findings: We report here the generation of large numbers of hNSC-derived oligodendroglial cells
by concurrent/sequential in vitro exposure to combinations of growth factors (FGF2, PDGF-AA), neurotrophins (NT3) and
hormones (T3). In particular, the combination FGF2+NT3+PDGF-AA resulted in the maintenance and enrichment of an
oligodendroglial cell population displaying immature phenotype (i.e., proliferation capacity and expression of PDGFRa,
Olig1 and Sox10), limited self-renewal and increased migratory activity in vitro. These cells generate large numbers of
oligodendroglial progeny at the early stages of maturation, both in vitro and after transplantation in models of CNS
demyelination.
Conclusions/Significance: We describe a reliable method to generate large numbers of oligodendrocytes from a renewable
source of somatic, non-immortalized NSC from the human foetal brain. We also provide insights on the mechanisms
underlying the pro-oligodendrogenic effect of the treatments in vitro and discuss potential issues responsible for the limited
myelinating capacity shown by hNSC-derived oligodendrocytes in vivo.
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Introduction
Development of therapeutic strategies to treat demyelinating
diseases requires improved understanding of the molecular and
epigenetic signals controlling the generation of mature oligoden-
drocytes from immature progenitors.
Short-term expandable cultures enriched in oligodendrocytes
and glial-restricted progenitors have been generated from human
embryonic neuroepithelial progenitors by means of epigenetic
stimulation and immunophenotype selection [1,2]. Also, subsets of
oligodendrocyte progenitors (OPC) are separated from the adult
human white matter based on their immunophenotype [3,4].
These cells promote extensive myelination in models of experi-
mental demyelination and congenital dysmyelination [4,5,6].
However, the limited OPC proliferation in vitro, which requires
large amount of human donor tissue, and their potential
immunogenicity might restrict their use in future clinical
applications. In this view, improved understanding of the
molecular and epigenetic signals controlling the generation of
mature oligodendrocytes from self-renewing, multipotent neural
stem cells (NSC) is crucial for the development of effective and
feasible transplantation approaches and in view of the more
challenging possibility to recruit endogenous progenitors for brain
repair.
Continuous, non-transformed NSC lines have been established
from the developing human (h) brain, either prospectively [7] or
by epigenetic stimulation in floating cultures [8,9,10] and in
adherent monolayers [11]. Human NSC display significant
proliferation potential and amenability to viral-mediated gene-
correction in vitro, coupled to lack of tumorigenicity upon grafting
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appropriately [12,13,14,15,16], also delivering neuroprotective
factors [17,18,19,20]. Thus, they might provide a continuous
supply of human neural precursors to be used for in vitro studies
and for developing cell therapy approaches for neurodegenerative
diseases of different origin [21,22,23]. However, in contrast to
their rodent counterpart, hNSC give rise to small numbers of
oligodendrocytes both in vitro [8,24,25,26] and after transplanta-
tion in the CNS [27,28,29][30].
Genetic and epigenetic in vitro manipulation of hNSC has been
tested in order to obtain cell populations enriched in oligoden-
droglia. Viral-mediated over-expression of oligodendroglial genes
[31] or immortalization of hNSC [32,33] has allowed the
generation of cell lines with appreciable oligodendroglial potential.
In contrast, molecules able to promote proliferation, survival and
maturation of rodent OPC from NSCs [34] are not similarly
effective on hNSCs, pointing to inter-species differences in growth
factor responsiveness [2,35,36]. Thus, additional studies aimed to
define factors able to promote the enrichment and expansion of
OPC from immature hNSCs are needed in the perspective of
developing clinically applicable therapeutic strategies.
The aim of this work was to obtain enriched and renewable
cultures of hNSC-derived oligodendroglial cells by means of
epigenetic manipulation. We report here that large numbers of
oligodendrocytes can be generated from long-term self-renewing
hNSCs by a simple in vitro protocol based on concurrent/
sequential in vitro exposure to combinations of growth factors
(FGF2, PDGF-AA), neurotrophins (NT3) and hormones (T3). In
particular, the combination FGF2+NT3+PDGF-AA resulted in
the maintenance and enrichment of a proliferating oligodendrog-
lial cell population displaying immature phenotype, limited self-
renewal and increased migratory activity in vitro. These cells
generate large numbers of oligodendroglial progeny at the early
stages of maturation, both in vitro and after transplantation in
models of CNS demyelination.
Results
Human NSCs express markers of immature
oligodendroglial cells
We evaluated the presence in hNSC of molecules involved in
the specification of the oligodendroglial lineage and in the
proliferation, survival and differentiation of oligodendroglial
precursors. Serially passaged neurospheres grown in EF medium
express the mRNA for several markers of immature and mature
oligodendroglial cells (Fig. 1A; NS). The presence of those markers
was confirmed by immunofluorescence on cells dissociated from
neurospheres and analyzed 24 hours after plating on an adhesive
substrate in EF medium (precursor cells; Fig. 1B–J’). A large
fraction of these cells expressed Ki67 (<70%; proliferation
marker; Fig. 1B), A2B5 (.90%; Fig. 1C) and nestin (.90%,
Fig. 1D), markers of immature neuroepithelial cells and neural
progenitors. A variable fraction of the hNSC population espressed
PDGFa receptor (PDGFRa; 56.0367.73%; Fig. 1E), Sox10
(64.7765.79% Fig. 1F), Olig1 (58.7168.59% Fig. 1G) and NG2
(19.7368.49%; Fig. 1H), markers of rodent and human-
oligodendroglial lineage cells [34,36]. Interestingly, <80% of the
NG2
+ cells espressed PDGFRa. Also, all the PDGFRa
+ cells
expressed Olig1, while only 80% of them espressed Sox10. A
minor proportion of the total cell population expressed the
Figure 1. Human NSCs express oligodendroglial markers. (A) RT-PCR analysis showing down-regulation (b-tubulin III, Ng2, PDGFRa, Olig-1,
Olig-2, Sox10) or up-regulation of transcripts (GFAP, Mag, Mog, Mbp) in hNSCs differentiated for 7 days in 2% FCS; Diff) compared to serially passaged
hNSCs grown in EF medium (neurospheres, NS; C-, negative control). Cells dissociated from neurospheres were plated on an adhesive substrate in EF
medium and analyzed by indirect immunofluorescence 24 hours later. Panels B–H show representative pictures of cells expressing proliferation
markers (Ki67; B), markers of immature neuroepithelial cells (nestin; D) and oligodendroglial progenitors (A2B5, C; PDGFRa, E; Sox10, F; Olig1, G; NG2,
H). Markers of mature neural cells: GFAP (I), b-Tubulin III and PSA-NCAM (J and J’ represent the same field). Nuclei were counterstained with dapi.
Scale bars: 30 mm (B, D, I), 50 mm (C, E, F, G, J, J’).
doi:10.1371/journal.pone.0010145.g001
Oligodendrocytes from hNSCs
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oligodendrocytes; not shown), GFAP (astroglia; 2.2760.54%;
Fig. 1I), b-tubulin III and PSA-NCAM (3.0161.10%; neurons;
Fig. 1J,J’). The distribution and expression pattern of PSA-NCAM
and b-tubulin III completely overlapped.
In order to drive progressive lineage restriction and cell
differentiation precursor cells were washed free of mitogens and
exposed to medium containing 2% FCS for 7 days. In
differentiated cultures (Fig. 1A; Diff) we found increased mRNA
levels for astroglial (GFAP) and oligodendroglial (MAG, MOG,
MBP) markers, paralleled by down-regulation of markers highly
expressed in precursors (i.e. NG2, PDGFRa, Olig2 and, to a lesser
extent, Olig1 and Sox10). On the contrary, mRNA levels for PLP-
DM20 (a major myelin protein), nestin and b-tubulin III were
similar or lower to those observed in precursors. Immunofluores-
cence analysis largely confirmed RT-PCR data, showing increased
numbers of astroglia (GFAP; 60.1665.31%) and neuronal cells
(TUJ1; 6.6063.29%), decreased proliferation activity (30.9167.17
and 16.4263.19 Ki67
+ and PCNA
+ cells, respectively) and




+ cells represented 4.8361.05%, 0.5960.51%, and
9.4263.11% of the total cell population, respectively). GalCer was
present in 2.4960.46% of the cells. Nestin expression was
maintained in <50% of GFAP
+ cells but was not observed in
TUJ1
+ or GalCer
+ cells. Expression of Sox10 and Olig1 was
maintained in 34.0169.67% and 53.79613.29% of the total




+ cell population in the









These data indicated that removal of mitogens and addition of
serum (a protocol that we call hereafter default differentiation protocol)
drives hNSC mainly towards the astroglial lineage. They also point
out that hNSCs contain a relevant population of proliferating
putative oligodendroglial progenitors.
Selected extrinsic signals direct hNSCs into
oligodendrocyte progenitors
We next checked whether removal of FCS from the medium
and addition of growth factors (FGF2, PDGF-AA), hormones
(T3) and neurotrophins (NT3) known to support proliferation,
survival and differentiation of rodent’s OPC could improve the
yield of hNSC-derived oligodendrocytes. The first treatment was
FGF2+PDGF-AA+NT3 (10, 20 and 20 ng/ml, respectively - FPN
medium) and the second was PDGF-AA+T3 (20 and 40 ng/ml,
respectively). Serially passaged neurospheres were washed free
of EF medium and mechanically dissociated. Cells were plated
in the different treatments for 7 days, then evaluating the
percentage of different cell types in the cultures by immunocy-
tochemistry. Treatment with either combinations resulted in




hNSC-derived cultures compared to the default differentiation
protocol (FCS; Fig. 2A) and this was paralleled by a 5-fold
reduction in the number of astrocytes (Fig. 2B; I, J). FPN
treatment was more effective than PDGF treatment in
generating oligodendroglial cells. Thus, we decided to investi-
gate in more detail the presence of oligodendroglial progenitors
in FPN-treated cultures. This analysis revealed an increase in
the number of PDGFRa
+ cells and Sox10
+ cells as compared to
FCS-treated cultures (Fig. 2C). Although the total percentage of
cells expressing proliferation markers was similar in the two
treatments (<35% and 16% of Ki67
+ and PCNA
+ cells,
r e s p e c t i v e l y ;F i g .2 C ) ,e x p o s u r et oF P Ni n c r e a s e do fa b o u t
two-fold the percentage of proliferating cells in the putative
oligodendroglial progenitor cell population (PDGFRa
+,O l i g 1
+,
Sox10
+ cells; Fig. 2D–F).
This result, coupled to the immature morphology of O4
+
(Fig. 2G) and GalCer
+ cells (Fig. 2H) and to the persistence of
NG2 expression in 20–50% of GalCer
+ cells (Fig. 2H) indicated
that a short treatment with FPN medium maintained and
expanded a population of putative oligodendrocyte progenitors
that could eventually differentiate in mature oligodendrocytes if
exposed to additional treatments.
A schematic of the qualitative and quantitative results for the
different culture conditions is shown in Fig. S1.
FPN priming increases the yield of hNSC-derived
oligodendrocytes in differentiated cultures
In order to assess whether the enrichment in oligodendroglial
progenitors obtained by FPN treatment could be actually exploited
to increase the yield in mature oligodendrocytes, hNSCs grown in
FPN medium for 7 days were shifted to FCS or PDGF-AA+T3
(known as pro-differentiating signals for rodent and human OPCs)
and grown for additional 10 days. Cells grown for 17 days in FCS
were used as control. Cultures were then analyzed for the presence
of neurons, astrocytes and oligodendroglial cells (Fig. 3A).
The additional 10-day differentiation period resulted in an
overall decrease of proliferation activity, reduced numbers of
immature progenitors and increased numbers of cells expressing
lineage-specific markers with respect to the values described in 7-
day treated cultures. In FPN-primed cultures we detected
reduced numbers of GFAP
+ cells and increased numbers of
TUJ1
+ cells as compared to FCS-primed cultures (Fig. 3B, J–J’),




+ cells, which reached 10–20% of the total
number of cells. This effect was more robust in FPN.FCS
cultures as compared to FPN.PDGF-AA+T3 cultures (Fig. 3C;
Fig. S1). The decrease in the percentage of KI67
+ cells observed
in FCS.FCS cultures (from 30% at 7DIV to 2% at 17 DIV) was
partially or totally prevented in FPN.FCS and FPN.PDGF-
AA+T3 cultures, respectively. A similar effect was observed on
the PDGFRa
+ cell population (Fig. 3D). The presence of higher
proportions of KI67
+ cells within the PDGFRa
+ cell population
in the FPN-primed cultures (either FCS- or PDGF-AA+T3-
treated) further confirmed the specific effect of this sequential
treatment in expanding and maintaining a population of hNSC-
derived oligodendroglial progenitors (Fig. 3E–G; a schematic of
the culture conditions and the percentages of cells immunoreac-
tive for lineage-specific and proliferation markers are summarized
in Fig. S1).
This conclusion was further supported by immunofluores-
cence analysis showing O4
+ cells displaying uni- and bipolar
morphology typical of oligodendrocyte progenitors (Fig. 3I, I’).
The GalCer
+ cell population (Fig. 3H, H’) was morphologically
heterogeneous, and included bipolar cells and cells displaying
features of non-myelinating oligodendrocytes. A variable
proportion of GalCer
+ and O4
+ cells co-expressed NG2 (Fig.
S2A,B). Importantly, NG2, GFAP and PSA-NCAM expression
were mutually exclusive in hNSC-differentiated culture and
identified oligodendroglial precursors, astroglia and cells of the
neuronal lineage, respectively, regardless the differentiation
protocol used (Fig. S2C–F). We did not detect MBP
+ cells,
suggesting that these differentiating conditions were not
sufficient to drive a substantial shift from oligodendrocyte
progenitors and pre-myelinating oligodendrocytes to mature
oligodendrocytes.
Oligodendrocytes from hNSCs
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expanded as neurospheres in FPN medium
Based on the results described above and with the aim of
generating a renewable source of hNSC-derived OPCs we
decided to test whether exposure of undifferentiated hNSCs to
FPN medium could expand human-derived oligodendrocyte
precursors in neurosphere cultures. We collected hNSCs grown
in EF medium and plated them in EF or in FPN medium,
establishing growth curves in the two different conditions.
Culturing hNSCs in FPN medium significantly reduced their
growth rate, still maintaining their self-renewing capacity for at
least 5 subculturing passages (Fig. 4A). While hNSCs in EF
medium generated typical floating neurospheres the FPN-treated
hNSCs showed a large proportion of small clusters and isolated
cells adhering to the flasks and showing the morphology of
migrating progenitors (Fig. 4B).
Figure 2. Selected epigenetic signals drive hNPCs to become oligodendrocytes in vitro. (A, B) Exposure of hNSCs to FPN or PDGF-AA+T3
increased the numbers of NG2
+,O 4
+ GalCer
+ oligodendroglil cells (A) and TUJ1
+ neuronal cells (B), while decreasing the numbers of astroglial cells (B)
compared to the default differentiation protocol (FCS). (C) Increased percentages of PDGFRa
+ and Sox10
+ cells are present in FPN-treated cultures as
compared to FCS-treated cultures. (D–F) FPN-treated cultures contain twice as much proliferating cells (Ki67
+) within the putative oligodendroglial
progenitor cell population (PDGFRa, D; Olig1, E; Sox10, F) as compared to FCS-treated cultures. (G–H) Immature morphology of O4
+ cells (G) and co-
expression of NG2 and GalCer in FPN-treated cells (H; orange colour represent merged signal). (I, J) Representative pictures of neurons (TUJ1) and
astrocytes (GFAP) in FPN (I) and FCS-treated (J) cultures. Data in A–F are expressed as the mean6SEM, n=224 independent experiments, 3–17 total
replicates. Data were analyzed by Two-way ANOVA followed by Bonferroni posttests. ***p,0.001,*p,0.05. Scale bars: 80 mm (G, I, J); 50 mm (H).
doi:10.1371/journal.pone.0010145.g002
Oligodendrocytes from hNSCs
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populations either in basal medium or in the presence of different
culture conditions (EF, FPN and PDGF-AA+T3). Our data
showed that all the treatments trigger a 2–3 fold increase in
migratory activity in both cell populations as compared to the
basal condition (Fig. 5A, B). In order to test the potential
‘‘intrinsic’’ difference in migratory activity of the two cell
populations, the migratory activity of FPN hNSCs was espressed
as fold increase to the migratory activity of EF hNSCs in each
culture condition. By doing so, we demonstrated that FPN-hNSCs
displayed a consistent 2–3 fold increase in migratory activity
compared to EF-hNSCs, both in basal media and in response to
the different treatments (Fig. 5C).
Finally, hNSCs grown for 5 passages in either FPN or EF
medium were differentiated by plating in FPN and EF medium,
respectively (4 days), and subsequently exposing them to FCS or
PDGF-AA+T3 for additional 10 days. After 4 days (Fig. 6A, B) we
found increased percentages of neurons and astrocytes (Fig. 6A),
higher numbers of NG2
+, PDGFRa
+ and Sox10
+ cells and similar
numbers of GalCer
+ (,3%) (Fig. 6B) and Olig1 (<70%; not
shown) in FPN- compared to EF-derived cultures. Interstingly,
<80% of NG2
+ cells co-expressed PDGFRa. This overlap
suggests that, under these culture conditions, NG2 and PDGFRa
co-expression identify OPCs developing from hNSCs. Both the
absolute percentage of Ki67
+ cells and the percentage of Ki67
+
cells within the PDGFRa
+ cell population were similar in EF- and
Figure 3. Priming with FPN medium increases the yield of oligodendrocytes. (A) Scheme summarizing the experimental protocol. (B–C)
FPN-primed cultures showed decreased numbers of astrocytes (GFAP) and increased numbers of neurons (TUJ1) compared to FCS-primed cultures
(B) as well as a 3–6 fold-increase in the number of NG2-, GalCer- and O4-expressing cells (C). (D) Percentages of cells expressing markers of
oligodendrocyte precursor and.proliferating cells in the different treatments. (E) Increased fractions of KI67
+ cells within the PDGFRa
+ cell population
in the FPN-primed cultures (either FCS- or PDGF-AA+T3-treated). Data are expressed as the mean6SEM, n=224 independent experiments with 3–12
total replicates. Comparisons between treatments were performed for individual antigens using Kruscal Wallis test followed by Dunn’s multiple
comparison test ***p,0.001, **p,0.01. (F, G) Representative confocal pictures of proliferating (Ki67, green) PDGFRa
+ (red) cell in FCS-(F) and
FPN.PDGF+T3-treated cultures (G). Nuclei counterstained with ToPro3 are shown separately (TP3; blue). (H–J’) Representative immunofluorescence
pictures showing the morphology of oligodendroglial cells (GalCer, H–H’; O4, I–I’), neuronal and astroglial cells (TUJ1 and GFAP; J–J’) in FPN-primed
(FPN.PDGF-AA+T3; H–J) compared to FCS treated cultures (FCS.FCS; H’–J’). Scale bars: 30 mm (F, G), 40 mm (H–I’), 100 mm (J, J’).
doi:10.1371/journal.pone.0010145.g003
Oligodendrocytes from hNSCs
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and FPN hNSCs for additional 10 days in either PDGF-AA+T3 or
FCS promoted their overall neuronal and astroglial differentiation,
as shown by increased percentage of TUJ1
+ and GFAP
+ cells, the
latter being reduced in PDGF-AA+T3 as respect to FCS-treated
cultures (Fig. 6C). In the presence of PDGF-AA+T3 we found
increased numbers of GalCer
+ in FPN-derived differentiated cells
with respect to their EF-derived counterpart (Fig. 6D). Similar
proportions of Olig1
+ (<50–60%) and Sox10
+ cells (<10%) were
maintained (not shown), regardless the treatment, and only a slight
increase in the proportions of the total PDGFRa
+ cells were
observed in FPN-derived differentiated cells (Fig. 6D). However,
the fraction of proliferating cells within the PDGFRa
+ cell
population was higher in FPN-derived hNSCs differentiated either
in FCS of in the presence of PDGF-AA+T3 (Fig. 6E–G).
These data indicated that growing hNSCs as neurospheres in
FPN medium allows the enrichment and expansion of an
oligodendroglial progeny, a relevant proportion of which retains
an immature phenotype when exposed to our differentiation
protocol. These results were further supported by: i) the presence
of increased proportions of Olig1
+ PDGFRa
+ (<20% versus 8%;
Fig. S3A) and, to a lesser extent, of Sox10
+PDGFRa
+ cells (<6%
vs 2%; Fig. S3B) in FPN vs EF hNSCs exposed to PDGF-AA+T3;
ii) the presence of variable proportions of PDGFRa
+ hNSCs
expressing nestin (Fig. S3C), but not PSA-NCAM (Fig. S3D) or
GFAP (Fig. S3E, F).
In our quantification experiments we provided all results as
percentages. In order to rule out the possibility that increased
percentages of putative OPCs might results from different
proliferation behavior of different cell populations depending on
the medium used, we analyzed the absolute numbers of cells and
the number of cells positive for each specific antigen used to
identify putative OPC, obtaining results consistent with our
original interpretation. Examples of absolute number analysis
are shown in Table S3.
When we applied the FPN priming paradigm to cortex (CTX)-
derived hNSCs [8], we found similar results in terms of
proliferation and differentiation capacity towards the oligoden-
droglial lineage. However, GalCer
+ oligodendrocytes generated
from CTX-derived FPN hNSCs cells consistently displayed a more
mature morphology (multiple branched processes and myelin-
sheet like formations) with respect to those generated by
telencephalon-derived FPN hNSCs cells (Fig. S4).
Myelinogenic competence of hNSCs in a model of focal
demyelination
We tested the ability of EF- and FPN-hNSCs to engraft and
differentiate following transplantation in a focal model of
demyelination induced with a single injection of lysolecithin in
the corpus callosum of adult mice. In this model, demyelination
occurs in about 48 hours and reaches maximum levels after 4–5
days. EF- or FPN-hNSCs were transplanted in the lesion site 48 h
after lysolecithin injection (Fig. 7A). A consistent fraction of
hNSCs (10–14% of the total number of transplanted cells),
detected by means of antibodies that specifically recognizes a
human nuclear protein (hNu), engrafted and survived up to 8
weeks post-transplantation (the longest time point analyzed) and
were found in regions close to the injection site, in the corpus
callosum and in the subventricular zone (SVZ) of the lateral
ventricles (Fig. 7B, B’). We observed higher numbers of engrafted
cells in the FPN hNSC-treated with respect to the EF hNSC
treated group (Fig. 7C) but no differences in rostro-caudal cell
distribution was observed between the two groups (3.9176295 mm
and 4.0736247 mm for EF and FPN hNSCs, respectively).
Human NSCs were also detected by using antibodies that
specifically recognized hMitochondia (hMit) and hNestin (hNest;
Fig. 7D–D’’), or hNu and hNest (Fig. 7E), which revealed
overlapping expression patterns. The engrafted hNSCs displayed
variable morphology, with cell processes extending in the brain
parenchima. The majority of them (.80%) expressed nestin
(Fig. 7H, J, L) and vimentin (not shown), markers of neuroepithe-
lial cells and immature glia.
Figure 4. hNSCs grown in FPN medium show limited expansion
and self-renewal. (A) Growth curves were established for EF and FPN
hNSCs as described in Methods. Each value point of the curves
represents the mean6SEM of three independent experiments. Data
were interpolated using a linear regression model and best fitted the
following equation: y = a + bx, where y is the LOG10 of the total
number of cells, x is the time (DIV), a is the intercept, and b is the slope.
Values of b6SEM are 0.0494860.00495 (EF) and 0.0244760.00512 (FPN)
**p=0.017. Dotted lines represent regression lines. (B) Human NSCs in
EF medium generated typical floating neurospheres, while FPN-treated
hNSCs showed small clusters and isolated bipolar cells adhering to the
flask. Scale bar, 200 mm.
doi:10.1371/journal.pone.0010145.g004
Figure 5. FPN-hNSCs show increased migratory activity. (A, B)
EF- and FPN-hNSCs display a 2–3 fold increase in migratory activity in
response to the different treatments. (C) FPN hNSCs display a 2–3 fold
increase in migratory activity compared to EF-hNSCs, both in control
medium and in response to the different treatments. Pictures show
representative fields for selected experimental conditions. Scale bars:
40 mm. Data are expressed as the mean 6 SE and derive from 2–4
independent experiments, 1–2 replicates for each experiment.
doi:10.1371/journal.pone.0010145.g005
Oligodendrocytes from hNSCs
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against lineage-specific markers showed that relevant proportion
of engrafted hNSCs (.80%) expressed Sox10 (Fig. 7F) and
Olig1 (not shown), suggesting the maintenance of the oligoden-
droglial potential shown in vitro.As m a l lf r a c t i o no fh N S C s
expressed bIV-Tubulin, a marker of early oligodendroglial cells
[37,38] (Fig. 7J, arrows). Most important, about 15% of
engrafted hNSCs expressed Glutathion-S-Transferase-p (GST-
p; Fig. 7G), a marker of mature oligodendrocytes in rodents
[39]. Only a small percentage of human-derived cells expressed
MBP (,2%; Fig. 7I) or the astrocytic markers Glutamine
synthase (GS, Fig. 7H) and GFAP (Fig. 7M). We did not detect
hNSCs expressing neuronal markers (TUJ1, not shown; PSA-
N C A M ,F i g .7 L ) .W ef o u n df e wc e l l so fd o n o ro r i g i ne x p r e s s i n g
the proliferation marker Ki67 localized along the lateral
ventricle (Fig. 7K). We did not find relevant differences in the
proportions of the different cell types among the engrafted FPN-
and EF- hNSCs.
In order to further strenghten these observations we transplant-
ed EF and FPN- hNSCs in the corpus callosum of young Shiverer
mouse, a model in which the lack of endogenous Mbp allows an
easier and more direct read-out of the myelinogenic competence
of the transplanted cells. Two months after transplant we observed
significant engraftment and migration of hNSCs, the majority of
which maintained nestin expression (Fig. S5). Similar results were
observed in mice analyzed 3 and 4 months after transplant (data
not shown).
Discussion
We describe here a simple and reliable method to generate large
numbers of oligodendroglial progenitors from a renewable source
of somatic, non-immortalized hNSCs by exposure to a specific
combination of growth factors, neurotrophins and hormones. Our
data clarify the mechanisms underlying the pro-oligodendrogenic
effect of the treatments in vitro and point to critical issues that
Figure 6. Myelinogenic potential of FPN hNSCs in vitro. (A–B) Percentages of neurons (TUJ1), astrocytes (GFAP; A) and oligodendrocytes
(NG2, PDGFRa and Sox10; B) in FPN- compared to EF-treated hNSCs four days after plating in their respective culture media. (C) Increased
percentages of TUJ1
+ and GFAP
+ cells at the end of the differentiation period (14 days) in FCS or PDGF-AA+T3 (D) Percentages of GalCer
+ cells in
PDGF-AA+T3-treated cultures derived from FPN- and EF- hNSCs (14 days). (E) Moderate increase in the total number of PDGFRa
+ cells and higher
proportion of Ki67
+PDGFRa
+ in FPN-derived hNSCs in comparison to the EF-derived counterpart. (F, G) Representative merged confocal pictures
showing PDGFRa
+ cells (red) expressing Ki67 (green) in FPN- (F) and EF-hNSCs (G) differentiated in the presence of PDGF-AA+T3. Nuclei
counterstained with ToPro3 (blue). Data are expressed as the mean6SEM, n=324 independent experiments, 2–16 total replicates. Comparisons
between the two cell populations were performed for different treatments and for individual antigens using Mann-Whitney test. **p,0.01, *p,0.05.
Scale bars: 30 mm (F, G).
doi:10.1371/journal.pone.0010145.g006
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PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10145Figure 7. Myelinogenic competence of hNSCs in a focal model of demyelination. (A) EF- or FPN-hNSCs (200.000 cells/animal) were
transplanted at the lesion site 48 h after lysolecithin injection. (B–C) Engrafted hNSCs (hNu; B) were present close to the injection site, in the corpus
callosum (CC) and in the subventricular zone (SVZ) of the lateral ventricles (LV) two months after injection. Nuclei counterstained with dapi (B’). (C)
Quantification of engrafted cells in mice transplanted with FPN- and EF-hNSCs. Data are expressed as the mean number of cells/brain 6SEM (n=5
animals/group; unpaired Student t test, p=0.07). (D–E) Double-labelling immunofluorescence using antibodies recognizing human Mitochondria
(hMit) and human Nestin (hNest; D–D’’) or hNu and hNest (E) showed overlapping distribution. (F–M) Engrafted hNSCs expressed nestin (H, J, L),
Oligodendrocytes from hNSCs
PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10145have to be considered when evaluating the myelinogenic
competence of hNSC-derived oligodendrocytes in experimental
models of CNS demyelination developed in mice.
Oligodendroglial cells express a set of growth factors receptors,
proteoglycans and transcription factors, according to their stage of
lineage progression. We provide evidence that, similarly to glial
restricted progenitors [2,4] and OPCs [40], the vast majority of
hNSCs are negative for the polysialilated form of the neural cell
adhesion molecule (PSA-NCAM), the expression of which in our
hands is restricted to cells of the neuronal lineage. Instead, hNSC
are positive for the A2B5 ganglioside-specific antigen (.90%) and
for the PDGFRa (.50%). A minor proportion (<20%) express
high levels of the chondroitin sulphate proteoglycan NG2, a
marker of intermediate and late OPCs and early pre-oligoden-
drocytes [40], and the majority of these cells co-express PDGFRa,
indicating overlap of these two markers in hNSC-derived OPCs.
In addition, <60% of undifferentiated hNSCs express the
transcription factors Olig1 and Sox10, which are widely expressed
in the oligodendroglial lineage and play fundamental roles in the
differentiation and maintenance of CNS oligodendroglial popula-
tions during development and in adulthood, in physiological
conditions and in disease [41,42,43,44]. The proportions of the
different cell types was stable over time (from passage 18 to 25),
indicating that relevant percentages of cells within the serially
passaged hNSC bulk population grown as neurospheres display a
molecular and immunochemical signature closely resembling that
described for OPC populations isolated from the human CNS by
means of immunopanning or FACS sorting [4,5,45].
Removal of mitogens (either with the addition of low serum
concentration or in serum-free conditions) results in the generation
of large numbers of oligodendrocytes from embryonic and post-
natal murine NSC lines (10–20% GalCer
+ and O4
+ cells)
[25,34,46] [47]. In contrast the yield of oligodendrocytes
generated from foetal hNSCs using similar differentiation
protocols is either not reported (directly isolated hNSCs)[7] or
shown to be low (epigenetically isolated hNSCs; ,3% of the total
number of cells in culture) [8,25,26,35,36,47,48]. The down-
regulation of mRNA levels for PDGFRa and Olig1/2 and Sox10
genes, coupled to up-regulation of myelin-specific genes in hNSC
cultures that we observed applying the default differentiation protocol
argued against the idea of reduced oligodendroglial potential of
human versus murine NSCs. However, the lack of robust
expression of markers of foetal and adult human pre- and early
oligodendrocytes (i.e. O4, GalCer)[36,40,49,50,51] or myelinating
oligodendrocytes (Mbp, Plp)[5] pointed to the incapability of this
treatment in sustaining either survival, proliferation or lineage
progression of human OPCs. Several reports indicate differences
in growth factor responsiveness between rodent and hNSCs as
regard to oligodendroglial production [2,35,36]. At the same time,
FGF2, PDGF-AA and neurotrophin 3 (NT3), molecules that
control rodent OPC proliferation, survival and migration in vitro
[34,52,53,54] and in vivo [55,56], are shown to promote
proliferation of spinal cord- [40] and white matter-derived human
OPC [4]. These observations suggest that murine and hNSCs
might share responsiveness to a set of growth factors that control
lineage specification, OPC survival and proliferation, envisaging
species-specific differences regarding the timing of differentiation
in response to these factors.
We found that a 7 day-exposure of hNSCs to FPN medium
increased the proportion of O4- and GalCer-expressing oligoden-
drocytes to 15–20% of the total number of cells in culture, a yield
that has never been reported so far from naı ¨ve hNSC.
Interestingly, we could maintain hNSCs as neurospheres in FPN
medium for at least 5 subculturing passages, achieving a moderate
but still important expansion of the cell population (10-fold versus
100-fold expansion in FPN- versus EF hNSCs). The morphology
of FPN-treated hNSCs, their increased migratory activity, the
increased percentages of proliferating cells expressing early OPC
markers and the reduced percentages of astrocytes in differentiated
cultures strongly support an effect of FPN priming in promoting
the expansion or survival of hNSC-derived OPCs at the expenses
of astroglial and, possibly, neuronal progenitors. However, we
cannot rule out the possibility of a treatment-induced lineage shift
(similar to that played by IGF-1 on murine NSCs) [57]. A detailed
comparative analysis of proliferating neuronal and glial population
is needed to address this issue.
A growth factor can mediate cell proliferation, survival or
differentiation depending on the stage of CNS development and/
or cell differentiation. The PDGF/PDGFRa signaling pathway
provides mitogenic and migratory signals in rodent [52,58] and
human [40] early OPCs, while later in development it has a major
survival effect [59]. The sequential and independent roles of
PDGF in proliferation and survival are mediated by PDGF-
mediated integrin activation, with a6b1 integrin playing a major
role [60,61,62]. We have recently shown that the vast majority of
hNSCs express a panel of adhesion molecules, among which a2,
a6, and b1integrins are the most represented [63], thus suggesting
a role for this signalling pathway in hNSCs and in their progeny.
Our data showing that exposure of FPN-primed cultures to
PDGF-AA is more efficient in delaying oligodendrocyte differen-
tiation compared to FCS (as shown by decreased percentages of
NG2-, GalCer- and O4-expressing cells coupled to a moderate
increase in PDGFRa
+Ki67
+ cells) are consistent with all these
notions. Thyroid hormone is key signal in brain development,
oligodendrocyte development and myelin protein gene expression
regulation [64,65] and can regulate oligodendroglial lineage and
maturation in neurospheres derived from the subventricular zone
of adult rats [66]. Similar to PDGF, it may act at multiple steps in
the development of oligodendrocytes [67]. Additional investigation
is needed to determine whether its effect on hNSCs is additive or
synergic to PDGF.
The large number of oligodendrocytes generated from hNSCs
did not reach the immunophenotypic features of myelinating cells
Interestingly, GalCer
+ oligodendrocytes generated from CTX-
derived FPN hNSCs cells consistently displayed a more mature
morphology (multiple branched processes and myelin-sheet like
formations) with respect to those generated by telencephalon-
derived FPN hNSCs cells. This suggests that the region-dependent
ability described for both rodent [46,47] ad human-derived NSCs
[48] to differentiate along the neuronal and glial lineage might
apply to the oligodendroglial lineage as well. Exposure of FPN-
primed cultures to BDNF, CNTF or IGF1, molecules known to
exert a maturational effect on rodent [68] and human OPCs [40]
resulted in more mature morphology of hNSC-derived oligoden-
drocytes, still without achieving MPB expression (A.Gritti,
unpublished results). Additional differentiation steps and a
Sox10 (F), bIV Tubulin (early oligodendroglial marker; J), GST-p (marker of mature oligodendrocytes; G). Few (,2%) human-derived cells expressed
MBP (I, arrows) and astrocytes markers (Glutamine synthase – GS, H; GFAP, M). We did not detect human cells expressing neuronal markers (PSA-
NCAM, L). Scattered hNSCs in the SVZ expressed the proliferation marker Ki67 (K). Scale bars: 200 mm (E), 100 mm (B, B’, F, J, L, M, I), 50 mm (D–D’’),
25 mm (G, H, K).
doi:10.1371/journal.pone.0010145.g007
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other molecules, alone or in combination, might be necessary to
push the maturation of hNSC-derived oligodendrocytes.
Our results indicate that hNSCs transplanted in a model of focal
CNS demyelination integrate, migrate and differentiate along the
oligodendroglial lineage. While higher numbers of engrafted cells
were observed in the FPN-transplanted group, the proportions of
EF- and FPN hNSC-derived Sox10-, Olig1- and GST-p-
expressing cells were similar. In addition, a very low yield in
MBP
+ cells was found in both groups. These results are in
apparent contrast with our in vitro data showing improved ability
of oligodendrocyte generation by FPN-treated hNSCs. Previous
studies reported from very low to moderate remyelination capacity
from naı ¨ve foetal hNSCs after transplantation in several animal
models of CNS de/dysmyelination [16,29] [30]. It was previously
shown that the in vivo environment of the acutely demyelinating
adult rat spinal cord is insufficient to stimulate the differentiation
of immature spinal cord-derived hNSCs [35] and of adult hOPCs
[69] to oligodendrocytes, pointing to the crucial role of species-
specific signals released at the lesion site in directing and
supporting oligodendrocyte migration and differentiation. Consis-
tent with this notion, we have recently reported that hNSCs
express the chemokine receptors CXCR4, CCR3, CCR6 and
CCR7 and migrate in vitro in response to the cognate human (but
not murine) ligands [63]. Also, the presence of significant numbers
of engrafted hNSCs still expressing nestin, Sox10 and Olig1 shown
in this and in other studies [31,48] indicates that .2 months might
be necessary to allow full maturation of engrafted hNSCs cells, due
to their slower timing of differentiation as compared to rodent
NSCs [70]. This notion is also supported by data indicating that
human glial-committed progenitors take at least 12 weeks to
extensively remyelinate the brain of Shiverer mice [5,6]. In
agreement with these findings, we observed a significant
engraftment and migration coupled to robust expression of nestin
in the majority of engrafted cells two months after transplantation
of EF and FPN- hNSCs in the corpus callosum of young Shiverer
mouse.
Lack of proper environmental signals and slow timing of hNSC
differentiation might indeed provide a key to reconcile the
apparent discrepancy between our in vitro and in vivo data. We
suggest that hNSCs grown as neurospheres in either EF or FPN
contain a large population of cells at the very early steps of the
oligodendroglial lineage. FPN priming allows the maintenance of a
larger pool of immature oligodendroglial progenitors, likely by a
selective more then and inductive mechanism, without signifi-
cantly modifying their timing of differentiation. Thus, they can
progress towards the oligodendroglial lineage only if they
encounter the proper sequence of signals in the appropriate
time-window. A similar mechanism has been previously proposed
to explain the moderate improvement in remyelination ability of
hNSCs genetically modified to over express Olig2 as compared to
the naı ¨ve counterpart [31]. However, the possibility remains that
hNSC-derived OPCs are unable to fully differentiate toward a full
myelinating phenotype, as suggested for adult OPCs residing in
the rodent gray matter [71,72], either due to intrinsic lineage
differences or consequently to a selection/induction by the in vitro
conditions.
We observed only few engrafted human cells retaining
proliferating ability (expressing Ki67) two months after transplan-
tation. These cells were exclusively localized in the SVZ, where the
mouse counterparts undergo the same events. These data are in
agreement with previous reports showing the persistence of few
proliferating hNSCs after long-term engraftment in the hippo-
campus, the other major neurogenic region of the adult brain [7].
Conclusions
Strategies aimed to improve the myelinogenic potential of
hNSCs in vivo include direct selection of committed progenitors
[3][5][45], genetic [31] or epigenetic manipulation [40]
[2,36,47,51] of hNSC towards the lineage of interest. We show
here that exposure of long-term expanded hNSCs isolated from
the developing human brain to defined combinations of pro-
oligodendroglial factors results in the generation of large numbers
of oligodendroglial cells at the early stages of lineage commit-
ment/differentiation. These cells represent a valuable tool for
modelling human oligodendrogenesis in vitro and for drug
discovery. Also, the availability of somatic non-immortalized,
expandable human neural precursors with low immunogenicity
and amenable to in vitro pre-differentiation to oligodendroglial
progenitors will facilitate the development and optimization of
cell-based therapy for demyelinating disorders. Finally, our results
might contribute to the development of efficient protocols to
generate oligodendrocyte cultures from patient-specific induced
pluripotent stem cells [73], which are emerging as a valuable
experimental model to study the pathophysiology of different
neurodegenerative diseases.
Materials and Methods
Isolation and culture propagation of hNSC
In this study we used two independent NSC lines established
and propagated from the diencephalic/telencephalic brain region
of two human (h) fetuses at 10.5-week gestational age. The first
NSC line used was previously described and characterized [8]; the
consent procedure and the ethichs committee that approved the
consent procedure were previously reported [8,12]. The second
NSC line was established from brain fetal tissue obtained from
Advanced Bioscience Resources, Inc., Alameda, CA, USA. The
use of human foetal tissue for the establishment of continuous,
non-transformed hNSC lines was approved by the San Raffaele
Scientific Institute Ethical committee. This NSC line was kindly
provided by Dr. S. Pluchino (Institute of Experimental Neurology,
San Raffaele Scientific Institute).
Cells were grown and expanded in mitogen-supplemented
serum-free medium (details can be found as File S1) by plating
10
4 cells/cm
2 at each subculturing passage in untreated tissue
culture flasks. Under these culture conditions both stem and non-
stem proliferative progenitors are present in the hNSC population.
Cells between passages 18 and 25 were used for the experiments.
The two hNSC lines behave similarly in all the experimental
conditions tested. Thus, results obtained from the two lines have
been pooled for statistical analysis.
Cultures of hNSC at different stages of maturation
Precursors (highly undifferentiated and proliferating cells)
were obtained by dissociating 10-day-old neurospheres, plating
single cells (20.000 cells/cm
2) and growing them for 24 hours in
serum-free medium containing EGF and FGF2 (EF medium).
Cultures of differentiated cells were obtained by exposing
precursors to mitogen-free medium containing either 2% FCS
(default differentiation protocol) or different combinations of
neurotrophin-3 (NT3), platelet-derived growth factor-AA
(PDGF-AA) and thyroid hormone (T3) and growing them for
7–17 days. Details on the composition of the culture media used
in different experimental conditions are available as File S1.
The extent of neuronal and glial differentiation was assessed by
using antibodies against lineage- and stage-specific markers, as
described below.
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Migration activity of hNSCs was tested using a Transwell
chamber system. Details can be found as File S1.
RT-PCR
Details on primer sequences and RT-PCR conditions are
available in Table S1.
Immunofluorescence of NSC cultures
Double-labelling immunofluorescence was performed as previ-
ously described [25]. Details can be found as File S1. Primary and
secondary antibodies used are listed in Table S2.
Transplantation of hNSCs in animal models of CNS
demyelination
Cell preparation. Serially passaged 10 day-old neurospheres
were collected by centrifugation (1.000 rpm615 min) and
mechanically dissociated. Viable cells were counted by Trypan
blue exclusion, washed in PBS and resuspended in PBS + 0.01%
DNAse (100.000 cells/ml). Cells were kept in ice until used.
Focal lesion. Male NOD SCID (NOD.CB17-Prkdc
scid/
NCrCrl) mice were obtained from Charles Rivers Laboratories
International Inc. (Wilmington, MA). Mice were housed in
microisolators under sterile conditions and supplied with
autoclaved food and water. The use of immunodefcient mice
avoided daily immunosuppression.
Two month-old mice were anesthesized with Avertin (Tribro-
moethanol, Sigma; St. Louis, MO, USA; 1.2%, 200 ml/10 g).
Lysolecithin (L-lysophosphatidylcholine; Sigma, St. Louis, MO;
1% in saline; 2 ml) were injected in the right corpus callosum.
Human NSCs grown in EF or in FPN (5 passages) were injected
at the lesion site (200.000 cells/2 ml) two days after lysolecithin
treatment. Controls received 2 ml of saline. Animals were
randomized in three experimental treatment groups: i) Vehicle
(n=2); ii) EF hNSCs (n=5); iii) FPN hNSCs (n=5). Eight weeks
post-transplantation (pt) mice were deeply anesthetized and
intracardially perfused with 0.9% NaCl followed by 4%
paraformaldehyde (PFA). Brains were isolated and processed for
immunohistochemistry as described below. Protocols regarding
animal treatment were approved by the Institutional Committee
for the Good Animal Experimentation of the San Raffaele
Scientific Institute (IACUC #202 and #314).
Tissue processing and immunofluorescence analysis
Perfused brains were equilibrated for 24 h in 10–20–30%
sucrose in PBS and quick frozen in optimal cutting-temperature
compound. Brains were cryostat cut in 16 mm-thick coronal
sections. Sections were collected the from the onset of the lateral
ventricle (Bregma AP +1.8 mm) to the hippocampal formation
(Bregma AP 22 mm) and ordered in 4 series on SuperFrostHPlus
glass slides (Menzel-Glaser, Braunschweig, DE); distance between
two consecutive sections in each series =64 mm. Details on
immunofluorescence analysis and on the quantification of cell
engraftment are available as File S1. Details on immunofluores-
cence analysis are available as File S1. Primary and secondary
antibodies used are listed in Table S2.
Statistical analysis
Two way ANOVA followed by Bonferroni’s post test was used
to compare different treatments, Kruscall-Wallis test followed by
Dunn’s multiple comparison test or Mann-Whitney test were
employed to compare percentages of immunoreactive cells in the
different treatments. For growth curves, data were interpolated
using a linear regression model and best fitted the following
equation: y = a + bx, where y is the estimated total number of
cells, x is the time (DIV), a is the intercept, and b is the slope. The
best-fit value, the Std error and the 95% confidence intervals of
the slope for each data set were calculated. The slope values were
then compared using F test. Statistical significance was accepted
with a p value ,0.05.
Supporting Information
Table S1 Primer sequence and RT-PCR conditions.
Found at: doi:10.1371/journal.pone.0010145.s001 (0.46 MB
DOC)
Table S2 Primary and secondary antibodies used.
Found at: doi:10.1371/journal.pone.0010145.s002 (0.06 MB
DOC)
Table S3 Absolute numbers (A, B) and averages (A’, B’) used to
calculate percentage values shown in Figure 3D (A and A’) and
Figure 6B (B and B’) in the main text. Values in each row of A and
B are the absolute numbers of nuclei (dapi; TOT) and of cells
expressing a specific antigen counted in 4–6 randomly selected
fields in one coverslip. The corresponding percentages are in
brackets. A. Different combinations of antibodies were tested:
PDGFRa/SOX10 (2 coverslips/treatment), PDGFRa/OLIG1 (2
coverslips/treatment) and PDGFRa/Ki67 (2 coverslips/treat-
ment). The mean values and the standard error of the mean
(SEM) are reported in A’. B. Values are from 3 coverslips in which
the anti-PDGFRa antibody was tested. The mean values and the
standard error of the mean (SEM) are reported in B’.
Found at: doi:10.1371/journal.pone.0010145.s003 (0.07 MB
DOC)
Figure S1 Cartoon summarizing the cell type specific quantifi-
cations after the different cultivation and priming conditions used
in this study. EF hNSCs: cells grown in EF medium FPN hNSCs:
EF cells shifted to FPN medium and serially subcultured in this
culture condition. Violet arrow indicates hours (h) or days (d) in
culture, black and blue arrows indicate the different cultivation
protocols, treatments (EF, FPN, FCS, PDGF+T3) are indicated in
boxes. Qualitative outcome of the different cultivation protocols
are indicated with thick arrows in boxes, arrows up or down in
comparison to FCS treatment (white boxes) or to EF (light blue
boxes). The reference Figure in which data are shown is indicated
in the boxes. Oligodendrocytes: GalCer+; Neurons: TUJ1+;
Astrocytes: GFAP+; Proliferating cells: Ki67+, PCNA+; Oligo
progenitors: NG2+, Olig1+, PDGFRa+, Sox10+. The percentages
of cells (mean6s.e.m).immunoreactive for lineage-specific and
proliferation markers in the different treatments and the
corresponding Figures in which these data are shown in the tables.
Found at: doi:10.1371/journal.pone.0010145.s004 (8.19 MB TIF)
Figure S2 Immunophenotypic signature of hNSC-derived
oligodendrocytes. (A–D) Merged immunofluorescence pictures
showing NG2+ cells (green), a fraction of them co-expressing
GalCer (A) and O4 (B). NG2+ cells do not co-express the
astrocytic marker GFAP (C) or the neuronal marker PSA-NCAM
(D). NG2, green; GalCer, O4, GFAP, PSA-NCAM, red; yellow-
orange indicates merged signal. Quantitative analysis (E) of hNSC
cultures exposed to different treatments shows similar numbers of
b-tubulin III and PSA-NCAM-expressing cells in the differentiated
cultures and an almost complete overlap of the two cell
populations (F; merged confocal picture: b-tubulin III, green;
PSA-NCAM, red; ToPro3, blue).
Found at: doi:10.1371/journal.pone.0010145.s005 (6.32 MB TIF)
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of an immature oligodendroglial progeny. Representative merged
confocal pictures of FPN hNSCs exposed for 10-day to PDGF-
AA+T3 showing PDGFRa+ (red) cells co-expressing Olig1(A,
green), Sox10+ (B, green) and nestin (C, green). PDGFRa+ cells
did not co-express PSA-NCAM (D, green) or GFAP (E, F; green).
Nuclei are counterstained with ToPro3 (blue).
Found at: doi:10.1371/journal.pone.0010145.s006 (6.64 MB TIF)
Figure S4 Oligodendroglial potential of CTX-derived hNSCs.
(A) Cortex (CTX)-derived human NSCs grown in EF medium
were plated either in 2% FCS or in the presence of FPN for 7 days.
After this priming time, medium was substituted with control
medium containing 2% FCS or PDGF-AA+T3 and cultures were
grown for additional 10 days. The cell type composition was
quantified at the end of the culture period. In FPN-primed
cultures the percentages of NG2+ and GalCer+ were increased
compared to FCS-treated cultures. Only minor differences were
observed in the percenteges of O4+ and TUJ1+ cells. Data are
expressed as the mean6SEM, n=2 independent experiments, 1–5
replicates/experiment. Comparisons between the different treat-
ments were performed for individual antigens using Kruscal-Wallis
test followed by Dunn’s multiple comparison test. **p,0.01 and
*p,0.05 vs FCS. (B) CTX hNSCs in FPN medium significantly
reduced their growth rate, still maintaining their self-renewing
capacity for at least 5 subculturing passages. Data are the
mean6SEM of three independent experiments. Data were
interpolated using a linear regression model and best fitted the
following equation: y = a + bx, where y is the LOG10 of the total
number of cells, x is the time (DIV), a is the intercept, and b is the
slope. Values of b6SEM are 0.0223760.00216 and
0.0155560.00168 for EF and FPN, respectively, **p=0.0307.
(C–F) Representative immufluorescence pictures of neurons
(TUJ1, red) and astrocytes (GFAP, green; C), and oligodendro-
cytes (O4 and GalCer, red; NG2, green; D–F) in FPN-primed
culture (FPN.PDGF+T3). Note the mature morphology of
GalCer-expressing cells.
Found at: doi:10.1371/journal.pone.0010145.s007 (5.27 MB TIF)
Figure S5 Human NSC transplantation in Shiverer mice. (A)
Two months after unilateral injection in the right corpus callosum
of post-natal day 20 Shiverer mice, LV.eGFP-T hNSCs are
migrated along the corpus callosum in the controlateral hemi-
sphere and show morphology and immunogenic features of
undifferentiated neural cells. GFP, green; nestin, red; blue, dapi;
yellow-orange, merged signal. Individual confocal pictures (106
magnification, 7 pictures for each channel and for the merged
series) were composed using the Photomerge tool of Adobe
Photoshop CS3. Higher magnification of the left (B) and right (C)
hemisphere showing co-localization of nestin (red) and GFP
(green) immunoreactivity. Right, injected site; left, controlateral
site. LV, lateral ventricles.
Found at: doi:10.1371/journal.pone.0010145.s008 (4.73 MB TIF)
File S1
Found at: doi:10.1371/journal.pone.0010145.s009 (0.04 MB
DOC)
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